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Abstract
Background: Progressive left ventricular (LV) diastolic dysfunction due to hypertension (HTN) alters left atrial (LA)
contractile function in a predictable manner. While increased LA size is a marker of LV diastolic dysfunction and
has been shown to be predictive of adverse cardiovascular outcomes, the prognostic significance of altered LA
contractile function is unknown.
Methods: A consecutive group of patients with chronic hypertension but without significant valvular disease or
prior MI underwent clinically-indicated CMR for assessment of left ventricular (LV) function, myocardial ischemia, or
viability. Calculation of LA volumes used in determining LA emptying functions was performed using the biplane
area-length method.
Results: Two-hundred and ten patients were included in this study. During a median follow-up of 19 months, 48
patients experienced major adverse cardiac events (MACE), including 24 deaths. Decreased LA contractile function
(LAEFContractile) demonstrated strong unadjusted associations with patient mortality, non-fatal events, and all MACE.
For every 10% reduction of LAEFContractile, unadjusted hazards to MACE, all-cause mortality, and non-fatal events
increased by 1.8, 1.5, and 1.4-folds, respectively. In addition, preservation of the proportional contribution from LA
contraction to total diastolic filling (Contractile/Total ratio) was strongly associated with lower MACE and patient
mortality. By multivariable analyses, LAEFContractile was the strongest predictor in each of the best overall models of
MACE, all-cause mortality, and non-fatal events. Even after adjustment for age, gender, left atrial volume, and LVEF,
LAEFContractile maintained strong independent associations with MACE (p < 0.0004), all-cause mortality (p < 0.0004),
and non-fatal events (p < 0.0004).
Conclusions: In hypertensive patients at risk for left ventricular diastolic dysfunction, a decreased contribution of LA
contractile function to ventricular filling during diastole is strongly predictive of adverse cardiac events and death.
Background
Left Ventricular (LV) diastolic dysfunction as a conse-
quence of chronic hypertension is a prevalent condition
associated with significant morbidity and mortality. Current
strong prognostic markers that reflect diastolic dysfunction
remain limited, but their identification may improve
treatment planning and monitoring of patients with chronic
hypertension. LA size reflects the duration and severity of
exposure to increased diastolic filling pressures in the LV
and is relatively load-independent. As LV diastolic impair-
ment progresses, effective diastolic filling becomes increas-
ingly dependent on LA contractile function until the LA
contractile reserve can no longer meet the demand of ele-
vated diastolic ventricular pressure[1-3]. While evidence
exists that LA enlargement is a strong predictor of adverse
cardiovascular outcomes in selected populations, there is
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left atrial contractile function in patients with chronic
hypertension at risk of diastolic dysfunction. While ‘ejection
fraction’ is the phrase used for reduction of ventricular cav-
ity volume, ‘emptying function’ is more appropriate for
reductions of atrial volume as the atria lack inflow valves
and empty passively as well as actively. Cardiac magnetic
resonance imaging (CMR) can quantify left atrial volume
and emptying functions with sufficient temporal and spatial
resolution and excellent reproducibility. Accordingly, this
study aims to test the hypothesis that altered LA contractile
emptying functions as measured by cine CMR can provide
strong prognostic information in patients with chronic
hypertension, beyond left atrial volume and other known
risk predictors in this population.
Methods
Patient Population
We studied a consecutive series of patients with history of
chronic hypertension medically treated for at least 6
months who were referred to undergo cardiac magnetic
resonance imaging (CMR) for clinical purposes. Patients
were referred either for a) evaluation for myocardial ische-
mia with stress CMR or b) assessment of regional and
global left ventricular function and myocardial mass.
Patients with any of the following were excluded: a) any
evidence of myocardial infarction by history, medical
record, or abnormal cardiac enzymes, b) any significant
aortic or mitral valvular dysfunction (moderate or severe
dysfunction by qualitative echocardiographic grading),
and c) confirmed (by biopsy) myocarditis, infiltrative
cardiomyopathy (including cardiac hemochromatosis, amy-
loidosis, or sarcoidosis), or pericardial disease. Other exclu-
sion criteria included concurrent unstable angina, NYHA
class IV heart failure, hemodynamic instability, claustro-
phobia precluding CMR, and metallic hazards. Patients
with patterns of late gadolinium enhancement consistent
with infiltrative cardiomyopathy or myocarditis were also
excluded. The institutional ethics committee of the Brig-
ham and Women’s Hospital (Partners Healthcare system)
approved the clinical follow-up activities of the study.
Clinical Evaluation
All patients underwent a detailed history immediately
before the CMR. Hypertension, hypercholesterolemia, dia-
betes, and family history of premature CAD were defined
by published criteria[4-7]. Significant smoking was defined
by >10 pack-years of tobacco use. History of CAD
included documented >70% stenosis on angiography or
history of coronary revascularization prior to CMR study.
CMR Imaging
All patients were studied supine in a 1.5T CMR system
(Signa
® CV/i, GE Healthcare, USA) with a 4-element or
8-element phased-array surface coil. CMR study con-
sisted of cine SSFP imaging (TR/TE 3.4/1.2ms, in-plane
spatial resolution 1.6 × 2 mm, matrix 192 × 160) of LV
function and late gadolinium enhancement imaging
(TR/TE 4.8/1.3ms, TI 200-300ms) for myocardial scar.
All images were acquired using retrospective ECG gat-
ing and breath-holding. Cine and late enhancement ima-
ging were obtained in 8-14 matching short-axis (8 mm
thick with 0 mm spacing) and 3 radial long-axis planes.
The 3 radial long-axis planes were prescribed at 60
degrees apart. Typical view per segment during a cine
SSFP acquisition was 12 yielding a temporal resolution
of approximately 45 ms and maintaining a breath-hold
of approximately 10-12 seconds for each slice location.
A previously described segmented inversion-recovery
pulse sequence for late enhancement imaging was used
[8] starting at 15 minutes after cumulative 0.15 mmol/
Kg dose of gadolinium-DPTA. A single reader categor-
ized late gadolinium enhancement as either typical
infarction (involving the subendocardium) or atypical
(subepicardial, patchy midwall or diffuse circumferential
subendocardial pattern).
CMR Quantitative Analysis of Left Atrial Volume and
Emptying Function
Quantitative Analysis of the left atrium is illustrated in
Figure 1. To measure the left atrial dimensions, manual
tracings were made of the left atrial area and long axis in
the radial 2-chamber and 4-chamber views. For each radial
view, tracings were performed at three phases: maximal
LA volume just before mitral valve opening, minimal LA
volume at mitral valve closure, and immediately prior to
Figure 1 Measurement of left atrial area (A) and length (L) in
4-chamber and 2-chamber views used in the calculation of the
left atrial volume indices (LAV) across different phases of the
cardiac cycle.
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by the previously validated biplane area-length method[9]
as follows: LA volume (ml) = 0.85*A2C*A4C/L, where A2C
and A4C are the LA areas on the 2-chamber and 4-cham-
ber views, respectively, and L is the shorter long-axis
length of the LA from either the 2-chamber or the
4-chamber views (Figure 1). Consistent with the recom-
mendation of published reports[10], all LA volumes were
normalized to the patient’s body surface area in subse-
quent analyses. Total LA emptying volume was calculated
as the difference between maximum (LAVmax) and mini-
mum LA volumes (LAVmin). Total LA emptying volume
was divided into LA passive emptying volume (VPassive)
and LA contractile volume (VContractile), in which VPassive
was calculated as the difference between LAVmax and the
LA volume preceding atrial contraction (LAVac)a n dV Con-
tractile was calculated as the difference between LAVac and
LAVmin. LA total, passive, and active emptying functions
(LAEFTotal,L A E F Passive,L A E F Contractile) were calculated
according to the following formulas:
LAEFTotal = (LAVmax − LAVac − LAVmin) ∗ 100/LAVmax
LAEFPassive = (LAVmax − LAVac) ∗ 100/LAVmax
LAEFContractile = (LAVac − LAVmin) ∗ 100/LAVac
In additon, we calculate the proportional contribution
of LA contraction during diastole by calculating the fol-
lowing parameters:
Contractile/Passive ratio = VContractile/VPassive
Contractile/Total ratio = VContractile/(VContractile +V Passive)
While left atrial dimension (in millimeters) was made
available to the attending physicians on the day of the
CMR, all other quantitative measurements of the left
atrium were not reported as part of the routine clinical
care.
CMR Quantitative Analysis of LV Function and Definition
of Myocardial Ischemia
All images were analyzed with specialized software (Cine-
Tool 2.80, General Electric Healthcare). We graded seg-
mental systolic wall motion as normal or abnormal in
each study and also graded segmental wall motion using
a 4-point scale (1 = normokinesia, 2 = hypokinesia, 3 =
akinesia, and 4 = dyskinesia) according to the standard
17-segment ACC/AHA nomenclature[11]. We inter-
preted late gadolinium myocardial enhancement (LGE)
as present or absent. Details of segmental wall motion
and LGE grading were as previously reported[12]. We
manually traced epicardial and endocardial borders of
matching short-axis cine locations at end systole and
end-diastole to determine the LV ejection fraction
(LVEF), end-diastolic volume index (LVEDVI), end-sys-
tolic volume index (LVESVI), and the LV myocardial
mass (end-diastole only)[13,14]. LVEF was measured by
standard Simpson’s Rule[14]. Presence of ischemia dur-
ing dobutamine stress was defined by standard criteria of
worsening regional wall motion by at least 1 grade,
matching on short and long-axis cine, as published in
prior reports[15]. Presence of ischemia during adenosine
stress perfusion was according to prior publication,
defined by existence of perfusion defect without infarc-
tion by LGE imaging[16].
ECG Interpretation
Resting 12-lead ECGs were obtained at a median of 1 day
(interquartile range: 0-7 days) from CMR. We confirmed
that no cardiac event or revascularization occurred
between the collection of ECG and the CMR study. ECG
interpretation was first performed by computer analysis
followed by visual over-reading by a single reader blinded
to the CMR results and the clinical outcome. ECG left
atrial enlargement was defined by a terminal negative P-
wave duration of > 40 ms and depth ≥ 1 mm measured
on lead V1. We used the Sokolow-Lyon index to indicate
LV hypertrophy on ECG[17].
Follow-Up
At least 6 months following the CMR, clinical informa-
tion was obtained from patient telephone interviews,
contacting patients’ physicians, and hospital records. A
standard questionnaire was used during telephone inter-
view. Survival was obtained from the National Social
Security Death Index in patients lost on first contact[18].
Major adverse cardiac events (MACE) included any of
the following: 1) all-cause mortality, 2) new acute myo-
cardial infarction, 3) unstable angina requiring hospitali-
zation, and 4) development or progression of heart
failure requiring hospitalization. New acute myocardial
infarction was defined by significant elevation of serum
troponins consistent with myocardial injury. Unstable
angina was defined by new chest pain hospitalization
without non-cardiac origin of chest pain, and with either
angiographic coronary stenosis of ≥70% or ischemia on
noninvasive imaging. Heart failure was defined by a need
for hospitalization for new or worsening symptoms of
heart failure as determined by the patient’s cardiologist
or primary internist. When a patient experienced >1
MACE, the first event was chosen. When ≥2M A C E
occurred simultaneously, the worse event was chosen
(death>MI>unstable angina>congestive heart failure).
Statistical Analysis
Baseline demographic differences, classified by the med-
ian LAEFContractile, were compared by Student’st - t e s to r
Fisher’s exact test. Kaplan-Meier distributions for MACE,
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the median value of LAEFContractile and were compared
by log-rank tests. We fitted Cox proportional-hazards
models to estimate the likelihood ratio chi-square (LRc
2)
and the unadjusted hazard ratios (HR) of all the variables.
We also assessed the univariable association of the pro-
portional contribution of LA contraction during diastole
(Contractile/Passive and Passive/Total ratios) with
MACE and other other events. To determine the set of
variables that were most strongly associated with LAEF-
Contractile, we performed linear regression using LAEFCon-
tractile as a continuous dependent variable, with all
variables in Table 1 treated as independent variables. The
prognostic association of LA size measurements and
mechanical function estimates were also determined
using similar analyses for all-cause mortality and non-
fatal events specifically. We tested the interobserver
agreement of LAEFContractile by Spearman correlation.
We performed 2 separate multivariable approaches to
analyze the predictive value of CMR variables for MACE
and all-cause mortality. In the first approach, we sought
to determine the strongest set of variables that were asso-
ciated with MACE, all-cause mortality, and non-fatal
events, respectively, in this study cohort. We used a step-
wise forward selection strategy and considered all clinical,
ECG, or left ventricular variables as listed in Table 2. A
p-value of 0.1 was used as criteria for variable inclusion
or exclusion. In the second approach, we aimed to deter-
mine the prognostic association, if any, of LAEFContractile
after adjustment to well-known risk predictors. There-
fore, we sought to determine if LAEFContractile remained a
significant predictor after adjustment to patient age, gen-
der, minimal left atrial volume, and left ventricular ejec-
tion fraction. The validity of the proportional-hazards
a s s u m p t i o n so ft h i sf i n a lm o d e lf o rM A C Ew a sa g a i n
tested and was valid for all the variables in this model.
All analyses were performed with SAS 9.1 (SAS Institute,
Cary, N.C.) for Windows.
Results
Baseline Characteristics
From a consecutive series of 225 patients with a history
of chronic hypertension, 3 (1%) had unsuccessful CMR
due to large body habitus or technical problem. Seven
patients (3%) had moderate or severe aortic or mitral
valvular dysfunction and were excluded from the study.
Five patients were lost to follow-up but were reported
alive. The remaining 210 (123 male, mean age 52 ± 16
years) formed the study cohort and were followed for a
median 19 months (range 6-50 months). Patients were
referred to undergo stress CMR for evaluation of ische-
mia (n = 106) or for assessment of left ventricular func-
tion (n = 104). Table 1 illustrates the demographical and
ECG features of the entire study cohort and also data
stratified by the median value of LAEFContractile (33%).
Baseline average left ventricular ejection fraction at rest
was low normal at 58 ± 13%. During the study period, 53
patients were referred to undergo coronary angiography
at a median 34 days (interquartile range 1-12 days) from
CMR study. Among them 38 patients (72%) were found
to have significant (>70%) luminal stenosis. LAEFContrac-
tile dichotomized by its median level did not show corre-
lation to the presence of angiographic coronary stenosis,
history of percutaneous coronary intervention, or history
of cardiac bypass surgery. Patients with LAEFContractile
below median value demonstrated a larger LA antero-
posterior dimension (42 ± 9.1 mm vs. 38 ± 6.2 mm, P <
0.01), lower left ventricular ejection fraction (55 ± 15%
vs. 61 ± 10%, P < 0.01), and higher left ventricular end-
systolic volume index (79 ± 57 ml/m
2 vs. 65 ± 41 ml/m
2,
P < 0.05). There was high inter-observer correlation in
quantifying LA volume (kappa statistic 0.83) across the
three time phases of the cardiac cycle.
Cardiovascular Outcome
At a median follow-up of 19 months (range 6 to 47
months), 48 MACE occurred. Among them were 21
cases of death, 3 acute myocardial infarction, 12 cases of
hospitalization for unstable angina, and 12 cases of con-
gestive heart failure requiring hospitalization.
Relationship of Left Atrial Enlargement by ECG, LV Mass,
and Left Atrial Volume and Mechanical Functions
Twenty patients (10%) demonstrated left atrial enlarge-
ment on ECG. The presence of left atrial enlargement by
ECG was only weakly associated with a higher than med-
ian LAVmin (P = 0.045) and did not demonstrate signifi-
cant correlation with above median LAVmax.L e f ta t r i a l
enlargement by ECG demonstrated poor sensitivity (16%)
but excellent specificity (93%) in identifying patients with
above median LAVmin. Left atrial enlargement by ECG
could not differentiate above or below median level of
LAEFContractile. While LV mass (g) is slightly higher in
patients with above median LAVmin ( 1 3 4±4 4v s .1 5 2±
55, P = 0.01), it was not significantly different among
patients with above or below median level of LAEFContrac-
tile. Left ventricular ejection fraction was negatively corre-
lated with LAVmin (r = -0.19, P = 0.008) and positively
correlated with LAEFContractile (r = 0.15, p = 0.04). By
multivariable linear regression, a history of atrial fibrilla-
tion on ECG, LAVmin, and left ventricular ejection frac-
tion were most strongly predictive of LAEFContractile.
Prognostic Association of Left Atrial Volume and Left
Atrial Mechanical Function of the Cohort
Univariable association of all variables with MACE, all-
cause mortality, and non-fatal events is listed in Table 2.
In the current study cohort, presence of LVH on ECG
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All Patients
(n = 210)
LA contractile function ≥ median
(n = 96)
LA contractile function < median
(n = 114)
P-value
Clinical Characteristics
Age in years 52 ± 16 52 ± 16 51 ± 15 NS
Female Gender (%) 87 (41) 42 (44) 45 (39) NS
Resting Heart Rate 71 ± 15 71 ± 15 71 ± 15 NS
Hx. of Diabetes (%) 71 (34) 32 (33) 39 (34) NS
Hx. of Hypercholesterolemia (%) 138 (65) 60 (63) 78 (68) NS
Heavy Tobacco Use (%) 56 (27) 24 (25) 32 (28) NS
Hx of PAD (%) 21 (10) 6 (6) 15 (13) NS
Hx. of Percutaneous Coronary Intervention
(%)
25 (12) 12 (13) 13 (11) NS
Hx. of Cardiac Bypass Surgery (%) 21 (10) 6 (6) 15 (13) NS
Hx. of Angiographic Coronary Stenosis
Before CMR (%)
45 (21) 22 (23) 23 (20) NS
Any Hx. of CAD before CMR (%) 41 (20) 17 (18) 24 (21) NS
Resting SBP 145 ± 25 148 ± 25 142 ± 24 NS
Resting DBP 75 ± 13 76 ± 12 75 ± 15 NS
Medication
Beta-blocker (%) 136 (65) 55 (57) 81 (71) 0.04
Calcium Blocker (%) 52 (25) 26 (27) 26 (23) NS
Angiotensin-converting enzyme inhibitor
(%)
103 (49) 51 (53) 52 (46) NS
Aspirin (%) 116 (55) 51 (53) 65 (57) NS
Nitrates (%) 23 (11) 9 (9) 14 (12) NS
Digoxin (%) 4 (2) 1 (1) 3 (3) NS
Rest Electrocardiogram
£
Left Atrial Enlargement on ECG (%) 24 (11) 13 (14) 10 (9) NS
Left Ventricular Hypertrophy on ECG 17 (8) 7 (7) 10 (9) NS
QRS duration (ms) 100 ± 25 97 ± 20 102 ± 27 NS
Left bundle branch block (%) 19 (9) 9 (9) 10 (9) NS
Right bundle branch block (%) 16 (8) 3 (3) 13 (11) 0.05
QTc interval 439 ± 39 433 ± 36 443 ± 40 0.09
Significant Q-waves by Minnesota Code
Criteria
19 (9) 12 (12) 7 (6) NS
CMR
Ao root dimen (mm) 28 ± 5 28 ± 4 28 ± 5 NS
LVEF (%) 58 ± 13 61 ± 10 55 ± 15 <0.01
LV mass (grams) 142 ± 50 139 ± 50 145 ± 51 NS
LVEDD (mm) 54 ± 8 53 ± 8 55 ± 8 NS
LVEDV index (ml/m
2) 164 ± 59 160 ± 54 167 ± 63 NS
LVESV index (ml/m
2) 73 ± 50 65 ± 41 79 ± 57 0.04
LA Volume index - end-systole (ml/m
2) 51 ± 20 45 ± 16 57 ± 21 <0.0001
LA Volume index - before atrial contraction
(ml/m
2)
41 ± 18 72 ± 31 88 ± 38 0.001
LA Volume index - end-diastole (ml/m
2) 30 ± 19 21 ± 9 39 ± 22 <0.0001
LAEFPassive (%) 19 ± 12 20 ± 12 18 ± 12 NS
LAEFContractile (%) 32 ± 15 42 ± 7 21 ± 13 <0.0001
LAEFTotal (%) 44 ± 16 54 ± 9 34 ± 15 <0.0001
Contractile/Passive Ratio 3.8 ± 19 5.1 ± 25 2.4 ± 8 <0.0001
Contractile/Total Ratio 0.57 ± 0.29 0.64 ± 0.18 0.50 ± 0.37 <0.0001
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or mortality but was associated with non-fatal cardiac
events (HR 4.43, 95% CI 1.54-12.77, P < 0.01). LV mass
measurement did not demonstrate significant associa-
tion with MACE. Decreasing left ventricular ejection
fraction, increasing LAVmin or LAVmax,a n dp r e s e n c eo f
late gadolinium myocardial enhancement were all asso-
ciated with non-fatal events but did not achieved signifi-
cant association with MACE or mortality. LAVmin (in
ml/m
2), LAEFContractile, and LAEFTotal demonstrated
Table 2 Univariable Association of Variables with All MACE, All-Cause Mortality, and Non-fatal Events
All MACE (N = 48) All-Cause Mortality (N = 21) Non-Fatal Events (N = 27)
LRc
2 HR (95% CI) P-value LRc
2 HR (95% CI) P-value LRc
2 HR P-value
Age (years) 0.41 1.01 (0.99-1.03) NS 0.51 1.01 (0.98-1.04) NS 0.02 1.00 (0.97-1.03) NS
Female Gender 2.12 1.63 (0.84-3.15) NS 4.65 2.72 (1.10-6.73) 0.03 0.01 1.04 (0.41-2.63) NS
Body Mass Index (m/kg
2) 1.62 0.96 (0.91-1.02) NS 0.19 0.98 (0.91-1.06) NS 2.19 0.94 (0.86-1.02) NS
Hx. Percutaneous Coronary Intervention 3.21 2.07 (0.93-4.56) 0.07 0.54 1.51 (0.51-4.48) NS 1.97 2.25 (0.73-6.98) NS
Hx. Coronary Bypass Surgery 3.69 2.25 (0.96-5.13) 0.05 0.23 1.35 (0.40-4.58) NS 3.44 2.87 (0.94-8.74) 0.06
Diabetes 0.49 1.27 (0.65-2.47) NS 0.01 1.00 (0.41-2.42) NS 0.07 1.14 (0.44-2.96) NS
Hypercholesterolemia 0.10 1.12 (0.54-2.34) NS 0.82 0.67 (0.28-1.61) NS 1.53 2.19 (0.63-7.59) NS
Hx. Heavy Smoking 0.60 1.31 (0.66-2.57) NS 0.17 0.82 (0.31-2.12) NS 1.09 1.65 (0.64-4.22) NS
Family Hx. CAD 1.00 0.66 (0.29-1.49) NS 0.33 0.77 (0.32-1.85) NS 0.47 0.67 (0.21-2.11) NS
Medications
Beta-blocker Use 4.68 2.63 (1.10-6.33) 0.03 4.27 4.65 (1.08-19.96) 0.04 1.08 1.80 (0.59-5.49) NS
Calcium Channel Blocker Use 1.08 1.44 (0.72-2.89) NS 0.01 0.95 (0.35-2.59) NS 1.66 1.87 (0.72-4.83) NS
ACE Inhibitor Use 0.05 0.93 (0.48-1.79) NS 0.01 0.98 (0.42-2.31) NS 0.74 0.66 (0.25-1.70) NS
Aspirin Use 0.97 1.42 (0.71-2.83) NS 0.04 0.92 (0.39-2.18) NS 1.43 1.88 (0.67-5.27) NS
ECG Variables
History of Atrial Fibrillation on ECG 2.17 2.22 (0.77-6.43) NS 1.22 2.30 (0.53-10.05) NS 0.66 1.87 (0.41-8.46) NS
Left Atrial Enlargement on ECG 0.01 1.04 (0.36-2.96) NS 0.62 0.45 (0.06-3.45) NS 0.61 1.65 (0.47-5.82) NS
LVH Voltage and Strain 1.92 1.97 (0.75-5.14) NS ** ** NS 7.58 4.43 (1.54-12.77) <0.01
Significant Q Waves 0.64 1.53 (0.54-4.39) NS 3.73 3.00 (0.98-19.12) 0.05 ** ** **
QRS Interval > 120 ms 0.39 0.72 (0.25-2.04) NS 0.29 0.67 (0.15-2.91) NS 0.01 1.08 (0.31-3.77) NS
Left Bundle Branch Block 1.21 1.71 (0.66-4.44) NS 0.05 1.18 (0.27-5.15) NS 3.31 2.84 (0.92-8.74) 0.07
Right Bundle Branch Block 0.23 0.70 (0.17-2.94) NS 0.28 1.49 (0.34-6.49) NS ** ** **
Significant ST Changes 1.61 1.72 (0.74-3.98) NS 0.06 0.83 (0.19-3.62) NS 3.05 2.55 (0.89-7.32) 0.08
Significant T Changes 0.03 1.08 (0.47-2.49) NS 0.10 1.19 (0.39-3.62) NS 0.07 0.84 (0.24-2.94) NS
Prolonged corrected QT Interval 5.15 2.23 (1.12-4.47) 0.02 1.42 1.76 (0.70-4.43) NS 4.58 2.99 (1.10-8.14) 0.03
CMR Variables of the LV
LVEDD (mm) 0.70 1.02 (0.98-1.06) NS 2.93 0.95 (0.90-1.01) 0.09 8.32 1.08 (1.02-1.14) <0.01
LVEF (per 10%) 2.59 0.84 (0.68-1.04) NS 0.04 1.03 (0.75-1.42) NS 5.3 0.71 (0.54-0.95) 0.02
LVEDVI (per 10 ml/m
2) 0.52 1.02 (0.97-1.07) NS 4.06 0.89 (0.80-1.00) NS 6.97 1.08 (1.02-1.13) <0.01
LVESVI (per 10 ml/m
2) 3.66 1.05 (1.00-1.10) 0.06 1.00 0.94 (0.82-1.07) NS 10.35 1.09 (1.03-1.14) 0.001
LV Mass (gram) 0.01 1.00 (0.99-1.01) NS 3.26 0.99 (0.98-1.00) 0.07 1.71 1.00 (1.00-1.01) NS
Segmental Wall Motion Abnormality 1.18 1.49 (0.73-3.06) NS 0.66 1.49 (0.57-3.93) NS 0.17 1.24 (0.44-3.49) NS
Abnormal LV LGE 6.33 2.47 (1.22-5.00) NS 2.12 2.08 (0.78-5.59) NS 3.91 2.69 (1.01-7.18) 0.05
CMR Variables of the LA
Anteroposterior LA Dimension (mm) 4.64 1.05 (1.00-1.09) 0.03 1.01 1.03 (0.97-1.10) NS 4.45 1.06 (1.00-1.12) 0.03
LAVmax (ml/m
2) 2.50 1.01 (1.00-1.03) NS 1.60 1.01 (0.99-1.04) NS 2.94 1.02 (1.00-1.04) 0.09
LAVac (ml/m
2) 3.16 1.02 (1.00-1.03) 0.08 2.79 1.02 (1.00-1.04) 0.10 2.99 1.02 (1.00-1.04) 0.08
LAVmin (ml/m
2) 6.28 1.02 (1.00-1.03) 0.01 6.48 1.02 (1.00-1.03) 0.01 3.84 1.02 (1.00-1.03) 0.05
LAEFPassive(per 10% reduction) 0.47 1.12 (0.81-1.57) NS 0.39 1.16 (0.73-1.86) NS 0.46 1.17 (0.74-1.86) NS
LAEFContractile(per 10% reduction) 18.84 1.75 (1.36-2.24) <0.0001 14.17 1.46 (1.20-1.77) <0.001 6.94 1.35 (1.08-1.70) <0.01
LAEFTotal (per 10% reduction) 10.91 1.45 (1.16-1.82) <0.001 10.80 1.38 (1.14-1.68) 0.001 5.05 1.29 (1.03-1.60) 0.02
Contractile/Passive ratio 10.64 0.94 (0.91-0.98) <0.001 1.47 0.88 (0.72-1.08) NS 11.9 0.93 (0.90-0.97) <0.001
Contractile/Total Ratio 10.48 0.39 (0.24-0.64) <0.001 8.75 0.21 (0.08-0.59) <0.01 1.21 0.48 (0.13-1.77) NS
* Too Few Events for Analysis.
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events, and all MACE. Figure 2 illustrates the Kaplan-
Meier curves demonstrating the time-to-event distribu-
tions for MACE, all-cause mortality, and non-fatal
events, stratified by the median level of LAEFContractile
(Figure 2A-C). The prognostic association of LAEFCon-
tractile with all MACE maintained its significance regard-
less of the presence or absence of ECG finding of LVH
(Figure 2D). For every 10% reduction of LAEFContractile,
unadjusted hazards to MACE, all-cause mortality, and
non-fatal events increased by 1.8, 1.5, and 1.4-folds,
respectively. By similar argument, preservation of the
proportional contribution of diastolic filling by atrial
contractile, as quantified by the Contractile/Passive or
Contractile/Total ratio, demonstrated strong association
with favorable outcome to MACE (unadjusted HR 0.94
and 0.39, respectively, both P = 0.001), with a preserved
Contractile/Total ratio portended to lower likelihood to
mortality (HR to mortality 0.21, P = 0.003). On the con-
trary, LA antero-posterior dimension only demonstrated
a weak unadjusted prognostic association with non-fatal
events but not with all-cause mortality (Table 2).
In the first multivariable approach, stepwise forward
selection strategy demonstrated that LAEFContractile was
the strongest multivariable predictor in each of the best
overall models of MACE, all-cause mortality, and non-
fatal events. For MACE prediction, LAEFContractile,h i s -
tory of cardiac bypass surgery, and left bundle branch
block on ECG were selected to form the best overall
model. Figure 3 presents the model LRc
2 of the selected
multivariate variables in each of the best overall models
for MACE, all-cause mortality, and non-fatal events,
respectively (Figure 3A-C). In the second multivariable
approach, adjusted to the patients’ age, gender, and LV
ejection fraction, LAEFContractile maintained strong and
independent prognostic association with MACE (model
LRc
2 increased from 4.99 to 22.02, P < 0.0001), all-
cause mortality (model LRc
2 increased from 4.54 to
15.88, P < 0.0001), and non-fatal events (model LRc
2
increased from 5.05 to 10.58, P = 0.005).
Figure 2 Kaplan-Meier curves illustrating the time-to-event distributions of MACE, all-cause mortality, and non-fatal events of the
study cohort, stratified by ≥ or < median LAEFContractile (Figure 2A-C). In addition, median LAEFContractile provided incremental prognostic
association with MACE beyond ECG evidence of left ventricular hypertrophy (ECG LVH) (Figure 2D).
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One hundred and six patients (50%) of the cohort
underwent CMR for evaluation of myocardial ischemia.
Among them 52 (49%) underwent dobutamine stress
cine and 54 (51%) underwent adenosine stress perfusion
imaging. Nineteen (17%) of the 106 patients were found
to have myocardial ischemia during stress CMR.
Twenty-six (25%) of the 106 patients experienced
MACE during study follow-up, among them 11 died.
Mean LAEFContractile was not significantly different
between patients with or without myocardial ischemia
(33 ± 11 vs. 35 ± 11, P = 0.38). In the subgroup of
patients who underwent CMR ischemia evaluation, pre-
sence of ischemia did not demonstrate any significant
association with MACE, all-cause mortality, and non-
fatal events (model LRc
2 0.90, 0.08, and 0,07, respec-
tively). When presence of myocardial ischemia was
entered into a model that contains LAEFContractile,t h e
significant associations of LAEFContractile with MACE
and all-cause mortality, respectively, were not altered
(hazard ratios of LAEFContractile adjusted to ischemia,
1.97 and 2.17; P = 0.0009 and 0.004, respectively).
Discussion
In this present study of hypertensive patients without sig-
nificant valvular disease or myocardial infarction, a
decreased contribution of LA contractile function to ven-
tricular filling during diastole was strongly predictive of
MACE, mortality, and non-fatal events. We found that in
these patients, proportional contribution of the LA con-
traction as measured by the LA Contractile/Total ratio
are strongly associated with MACE and patient mortality.
These observations were true even after adjustment for
age, gender, LA volume and left ventricular ejection frac-
tion. This postulates that altered LA mechanical contrac-
tile function by CMR in patients with or at risk for
diastolic dysfunction from hypertension provides unique
and independent prognostic value to adverse cardiovas-
cular outcomes. To our knowledge, this is the first study
which demonstrates a relationship between altered LA
contractile function and CV outcomes, including mortal-
ity, in hypertensive patients.
In normal humans, passive emptying of the LA (a com-
bination of the reservoir and conduit functions of the LA)
during ventricular diastole contributes 75-80% of LV fill-
ing. LA contractile function normally contributes approxi-
mately < 25% of the total LV filling volume[19], but
becomes increasing important to LV diastolic filling as
ventricular stiffness progresses. In the mild stage of
impaired LV relaxation, the LA contractile function
increases and can contribute up to 38% of LV filling[1].
However, as LV stiffness progresses to moderate or severe
range with marked increases in LV filling pressures, the
contribution of LA contraction falls below the normal
contribution, and the LA becomes mainly a passive con-
duit for ventricular filling [3,10]. Given what is known
Figure 3 Multivariable Best Overall Models for MACE, All-Cause Mortality, and Non-Fatal Events. The respective LRc
2 of the predictors in
each model is illustrated by the number on top of each column.
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sent findings would seem to suggest that the increased
risk of MACE and mortality might be conferred mostly on
those patients with more severe (i.e. grade III or IV)
restrictive LV diastolic dysfunction and thus decreased LA
contractile function. Indeed, although patients in the gen-
eral population with all grades of diastolic function are at
increased risk of adverse CV outcomes and mortality, the
risk is most pronounced in those patients with restrictive
(grade III or IV) LV diastolic function [20]. This is also
consistent with the known limited ability of the LA to
reflect changes in mild or moderate LV diastolic dysfunc-
tion. Pritchett et al. has previously reported that in the
general population, indexed LA volume has the highest
sensitivity and specificity for the detection of severe (grade
III or IV) LV diastolic dysfunction [21]. The same may be
true of LA contractile function.
In this study, CMR is able to quantify LA contractile
function at high spatial resolution for border delineation
and adequate temporal resolution to capture LA motion
throughout the cardiac cycle. We demonstrated such LA
quantitative results are highly reproducible. While echo-
cardiographic studies have assessed the relationship
between LA volume and clinical outcomes, the prognostic
relationship between the different components of LA
mechanical function and clinical outcomes has not been
well studied. We postulate that exposure of the LA myo-
cardium to elevated left ventricular diastolic pressure can
result in LA myopathy which can be quantified by LAEF-
Contractile utilizing CMR as in the current study. Conformed
to the existing body of echocardiographic literature, we
used planar images of the LA acquired along its long axis
and then used two dimensional measurements and stan-
dardized formulas to calculate LA volumes by the biplane
area length method. It is therefore conceivable that the
CMR findings of our study can be applied to similar
patients undergoing echocardiographic assessment.
LA size has long been reported to be a sensitive and
load-independent marker of both the severity and duration
of LV diastolic dysfunction[22-24]. There is substantial
and growing evidence pointing to the clear prognostic
value of LA size in selected clinical populations. In the
general population, increased LA volume has been shown
to predict atrial fibrillation [23-28] stroke [22,29], and inci-
dence of heart failure [30,31]. In addition, several authors
have demonstrated the role of increased LA volume in
predicting mortality in populations with pre-existing cardi-
ovascular diseases, such as post-myocardial infarction or
with LV dysfunction [32-35]. We believe that this study
adds to this knowledge by showing that in patients with
chronic hypertension, LA contractile function represents
an additional prognostic tool by characterizing the burden
of underlying diastolic dysfunction not assessed by current
imaging techniques. Moreover, this study demonstrates
the feasibility of using CMR to assess the LA in the clinical
setting to predict cardiovascular outcomes.
Limitations
There are a number of study limitations. This study was a
retrospective referral-based cohort study at a single cen-
ter. All of the subjects studied had been referred for
CMR examination, while the clinical indications of such
were appropriate, the generalizability to other popula-
tions with hypertension may be limited. Only 50% of the
current study cohort underwent stress CMR evaluation
for myocardial ischemia. While we found that presence
of myocardial ischemia did not seem to alter the prog-
nostic significance of LA contractile function with the
clinical outcomes, the current report does not have the
study design or power to properly address whether myo-
cardial ischemia could have been a confounding variable.
The method of LA volume quantitation in this study can
only provide estimates of LA volumes since it has not
been validated against the axial stacked volumetric ima-
ging. The study is also limited by its sample size and the
small number of patients who experienced MACE, there-
fore some degree of model overfitting in the multivari-
able analyses may have occurred. For this reason,
confirmation of the current study findings and explora-
tion of potential therapeutic implications that can alter
LA mechanics are necessary in a larger prospective study.
Finally, concurrent load-independent measures of LV
diastolic function such as tissue Doppler velocity are not
available in the current study, thus prohibiting probing in
the mechanism of the significant prognostic findings
being reported in the current study. Such association of
LA contractile function with imaging markers of diastolic
dysfunction and serum markers such as naturetic peptide
levels[36], will need to be studied prospectively.
Conclusions
In patients with a history of chronic hypertension, a
decreased contribution of LA contractile function to ven-
tricular filling during diastole appears to be a novel predic-
tor of adverse cardiac events and death.
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